1. Home
  2. JFIN vs NGNE Comparison

JFIN vs NGNE Comparison

Compare JFIN & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

JFIN

Jiayin Group Inc.

HOLD

Current Price

$6.17

Market Cap

330.9M

Sector

Finance

ML Signal

HOLD

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$24.10

Market Cap

327.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JFIN
NGNE
Founded
2011
2003
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
330.9M
327.8M
IPO Year
2018
2014

Fundamental Metrics

Financial Performance
Metric
JFIN
NGNE
Price
$6.17
$24.10
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$60.13
AVG Volume (30 Days)
63.9K
150.5K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
13.16%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$925,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$1.35
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.73
$6.88
52 Week High
$18.70
$37.27

Technical Indicators

Market Signals
Indicator
JFIN
NGNE
Relative Strength Index (RSI) 40.82 66.14
Support Level $5.81 $19.44
Resistance Level $7.22 $36.37
Average True Range (ATR) 0.32 2.02
MACD -0.01 0.67
Stochastic Oscillator 30.00 75.43

Price Performance

Historical Comparison
JFIN
NGNE

About JFIN Jiayin Group Inc.

Jiayin Group Inc is China's technology service group. It is an enterprise engaged in technological innovation services. It is committed to using big data, cloud computing, artificial intelligence and other technologies to connect consumers and financial institutions in consumption scenarios so that every user can enjoy efficient and convenient technology services. The company has engraved technological innovation into the company's development genes since its establishment, adheres to the dual drive of digital plus technology, and focuses on building a cloud service platform and intelligent risk control system with big data drive as the core concept.

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Share on Social Networks: